Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Icahn School of Medicine at Mount Sinai, BioMedical Engineering and Imaging Institute, New York City, New York, USA.
J Magn Reson Imaging. 2023 Dec;58(6):1660-1679. doi: 10.1002/jmri.28828. Epub 2023 May 26.
Renal diseases pose a significant socio-economic burden on healthcare systems. The development of better diagnostics and prognostics is well-recognized as a key strategy to resolve these challenges. Central to these developments are MRI biomarkers, due to their potential for monitoring of early pathophysiological changes, renal disease progression or treatment effects. The surge in renal MRI involves major cross-domain initiatives, large clinical studies, and educational programs. In parallel with these translational efforts, the need for greater (patho)physiological specificity remains, to enable engagement with clinical nephrologists and increase the associated health impact. The ISMRM 2022 Member Initiated Symposium (MIS) on renal MRI spotlighted this issue with the goal of inspiring more solutions from the ISMRM community. This work is a summary of the MIS presentations devoted to: 1) educating imaging scientists and clinicians on renal (patho)physiology and demands from clinical nephrologists, 2) elucidating the connection of MRI parameters with renal physiology, 3) presenting the current state of leading MR surrogates in assessing renal structure and functions as well as their next generation of innovation, and 4) describing the potential of these imaging markers for providing clinically meaningful renal characterization to guide or supplement clinical decision making. We hope to continue momentum of recent years and introduce new entrants to the development process, connecting (patho)physiology with (bio)physics, and conceiving new clinical applications. We envision this process to benefit from cross-disciplinary collaboration and analogous efforts in other body organs, but also to maximally leverage the unique opportunities of renal physiology. LEVEL OF EVIDENCE: 1 TECHNICAL EFFICACY STAGE: 2.
肾脏疾病给医疗系统带来了重大的社会经济负担。人们普遍认识到,开发更好的诊断和预后方法是解决这些挑战的关键策略。在这些发展中,MRI 生物标志物至关重要,因为它们具有监测早期病理生理变化、肾脏疾病进展或治疗效果的潜力。肾脏 MRI 的发展涉及到重大的跨领域计划、大型临床研究和教育项目。在这些转化努力的同时,需要更大的(病理)生理学特异性,以与临床肾病学家合作并增加相关的健康影响。ISMRM 2022 年成员发起的研讨会(MIS)以肾脏 MRI 为重点,旨在激发 ISMRM 社区提出更多解决方案。这项工作是 MIS 演讲的总结,致力于:1)教育成像科学家和临床医生关于肾脏(病理)生理学以及临床肾病学家的需求,2)阐明 MRI 参数与肾脏生理学的联系,3)介绍评估肾脏结构和功能的主要 MR 替代物的现状及其下一代创新,以及 4)描述这些成像标志物在提供有临床意义的肾脏特征描述以指导或补充临床决策方面的潜力。我们希望继续保持近年来的势头,为发展过程引入新的参与者,将(病理)生理学与(生物)物理学联系起来,并构想新的临床应用。我们设想这个过程将受益于跨学科合作和其他身体器官的类似努力,同时最大限度地利用肾脏生理学的独特机会。证据水平:1 技术功效阶段:2